Regeneron(REGN) Prnewswire·2025-03-10 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the company's pricing practices for its product Eylea during the class period from November 2, 2023, to October 30, 2024 [1]. Summary by Sections Allegations - The complaint alleges that Regeneron made materially false and misleading statements by failing to disclose payments made to distributors to subsidize credit card fees for Eylea customers [1] - These undisclosed payments led to a price concession that lowered Eylea's selling price, providing a competitive advantage in a sensitive pricing environment for retina practices [1] - As a result, Regeneron allegedly overstated Eylea sales and misrepresented its business operations and prospects, violating the False Claims Act by not reporting these payments as price concessions [1] Class Action Details - Shareholders who purchased shares of REGN during the specified class period are encouraged to register for the class action, with a deadline set for March 10, 2025 [2] - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, and there is no cost or obligation to participate [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]